E Fund Management Co. Ltd. decreased its stake in Novavax, Inc. (NASDAQ:NVAX – Free Report) by 80.0% during the 2nd quarter, Holdings Channel reports. The firm owned 15,904 shares of the biopharmaceutical company’s stock after selling 63,610 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Novavax were worth $201,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of NVAX. Victory Capital Management Inc. purchased a new stake in Novavax during the 4th quarter worth approximately $72,000. Allianz Asset Management GmbH raised its stake in Novavax by 45.9% in the 4th quarter. Allianz Asset Management GmbH now owns 634,692 shares of the biopharmaceutical company’s stock valued at $3,047,000 after purchasing an additional 199,771 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in Novavax by 62.4% in the 4th quarter. Rafferty Asset Management LLC now owns 1,611,840 shares of the biopharmaceutical company’s stock valued at $7,737,000 after purchasing an additional 619,370 shares in the last quarter. Pennant Investors LP acquired a new stake in Novavax during the 4th quarter worth $289,000. Finally, Coatue Management LLC purchased a new stake in shares of Novavax during the fourth quarter worth $7,294,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.
Novavax Stock Down 0.3 %
NVAX stock opened at $12.52 on Friday. Novavax, Inc. has a 52-week low of $3.53 and a 52-week high of $23.86. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -3.95 and a beta of 2.04. The business has a fifty day moving average of $13.01 and a two-hundred day moving average of $10.60.
Wall Street Analyst Weigh In
NVAX has been the topic of a number of recent research reports. B. Riley restated a “buy” rating and set a $23.00 price target (down from $25.00) on shares of Novavax in a research report on Monday, August 12th. JPMorgan Chase & Co. boosted their target price on Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Monday, August 12th. Finally, Bank of America increased their price target on Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, June 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Novavax has an average rating of “Hold” and a consensus target price of $15.80.
View Our Latest Research Report on Novavax
About Novavax
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Read More
- Five stocks we like better than Novavax
- What is a Secondary Public Offering? What Investors Need to Know
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Most active stocks: Dollar volume vs share volume
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Investors Need to Know to Beat the Market
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX – Free Report).
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.